🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 66 of 173

  1. US 10154974

    Use of abscisic acid for the prevention and treatment of malaria

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10154881

    Methods and compositions for tissue adhesives

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10154669

    Improving color and release profile of resin compositions comprising silver nanoparticles

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10155003

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10151756

    Predictive markers for polyamine inhibitor cancer therapies

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10150948

    Compositions and methods for producing and administering brown adipocytes

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10150753

    Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10149897

    Scaffolds for cell transplantation

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10149906

    Targeting microbubbles

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10149836

    Isoxazole treatments for frontotemporal dementia

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10150806

    Aldehyde tags, uses thereof in site-specific protein modification

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10144767

    Anti-microbial peptides and coatings

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10143660

    Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10143658

    Multistage delivery of active agents

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10138298

    Anti-IL-2 antibodies and compositions and uses thereof

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10137299

    Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10137184

    Scaffolds for cell transplantation

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10138486

    Inhibitors of DEK protein and related methods

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10138279

    Compositions and methods for Bacillus anthracis vaccination

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10138466

    Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10137100

    Administration of serine protease inhibitors to the stomach

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10131668

    Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10130723

    TCO conjugates and methods for delivery of therapeutic agents

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10130711

    Chemical structures for localized delivery of therapeutic agents

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10130604

    Composition and method for treating neurodegenerative disease

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10130560

    Bioactive “smart” dental composite materials

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10131880

    Pluripotent human adipose adult stem cells: isolation, characterization and clinical implications

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10126309

    Method for the detection of an albumin isoform

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10125193

    Chimeric antigen receptors and methods of making

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10123759

    Systems, compositions, and methods for local imaging and treatment of pain

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10125105

    Triazabutadienes as cleavable cross-linkers

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10125167

    Compositions and methods for treating MRSA infections and for sensitizing MRSA to beta-lactam antibiotics

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10125131

    Selective HDAC3 inhibitors

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10125128

    GLS1 inhibitors for treating disease

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10119140

    Methods for enhancing or decreasing the levels of MIR124 and MIR29 in subjects with muscular dystrophy

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10118942

    Toll-like receptor 2 ligands and methods of making and using thereof

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10117915

    Modulation of yeast-based immunotherapy products and responses

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10117928

    Annexin II compositions

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10117912

    Drug delivery method

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10117871

    3-hydroxypyrimidine-2,4-dione-5-carboxamides as potent inhibitors of HIV

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10117878

    Ligands for nematode nuclear receptors and uses thereof

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10117945

    mTORC1 inhibitors

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10117907

    Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases

    Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10113167

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10112917

    Therapeutic compounds

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10111937

    Method of reducing accumulation of intracellular tingible body macrophages

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10111926

    Selectively targeted antimicrobial peptides and the use thereof

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10111861

    Treatment of breast cancer

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.